Industry Partner News: Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical Trial


Summit announces the completion of the initial 24-weeks of dosing of ezutromid in patients with DMD in its Phase 2 clinical trial called PhaseOut DMD. With this milestone, Summit continues to expect to report results from this initial 24-week dosing period in the first quarter of 2018. The 24-week results are expected to include data from muscle biopsies, MRI and functional tests, as well as safety data.

For more information, please see the Summit press release by clicking here.